UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): March 16, 2016

 

 

Mallinckrodt public limited company

(Exact name of registrant as specified in its charter)

 

 

 

Ireland		001-35803		98-1088325
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

Perth House, Millennium Way,

Chesterfield, Derbyshire S41 8ND, United Kingdom

(Address of principal executive offices)

+44 124 626 3051

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

---

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 16, 2016, the shareholders of Mallinckrodt plc (the “Company”) approved the Mallinckrodt Pharmaceuticals 2016 Employee Stock Purchase Plan (the “Plan”) at the Company’s 2016 Annual General Meeting of Shareholders (the “Annual Meeting”). The purpose of the Plan is to serve as an incentive for employee recruitment and retention by providing the Company’s employees with an opportunity to purchase ordinary shares through accumulated payroll deductions. There are 5,000,000 ordinary shares available for issuance under the Plan.

The above description of the Plan does not purport to be complete and is qualified in its entirety by the full text of the Plan set forth as Exhibit 10.1 hereto and incorporated herein by reference.

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

At the Annual Meeting, the shareholders:

 

•

elected all 11 of the Company’s nominees for director;

 

•

approved, in a non-binding vote, the appointment of Deloitte & Touche LLP to serve as the Company’s independent auditors for the fiscal year ending September 30, 2016 and authorized, in a binding vote, the Audit Committee to set the auditor’s remuneration;

 

•

approved, in a non-binding advisory vote, the compensation of the Company’s named executive officers described in the proxy statement;

 

•

approved the Mallinckrodt Pharmaceuticals 2016 Employee Stock Purchase Plan;

 

•

authorized the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares; and

 

•

authorized the price range at which the Company can re-allot shares it holds as treasury shares (Special Resolution).

The final results for each of the matters submitted to a vote of shareholders at the Annual Meeting are as follows:

Proposal 1. To re-elect eleven (11) directors to hold office until the Company’s next Annual General Meeting of Shareholders:

 

Nominees		For				Against				Abstain				Broker Non-Votes
(a) Melvin D. Booth			86,234,318				99,117				47,382				10,311,205
(b) David R. Carlucci			86,184,839				148,432				47,546				10,311,205
(c) J. Martin Carroll			86,235,112				97,865				47,840				10,311,205
(d) Diane H. Gulyas			86,196,565				137,770				46,482				10,311,205
(e) Nancy S. Lurker			86,176,195				159,739				44,883				10,311,205
(f) JoAnn A. Reed			86,241,362				97,511				41,944				10,311,205
(g) Angus C. Russell			85,176,378				1,156,421				48,018				10,311,205
(h) Virgil D. Thompson			86,114,471				220,017				46,329				10,311,205
(i) Mark C. Trudeau			86,218,763				116,331				45,723				10,311,205
(j) Kneeland C. Youngblood, M.D.			86,236,502				101,448				42,867				10,311,205
(k) Joseph A. Zaccagnino			86,233,224				100,317				47,276				10,311,205

 

2

---

Proposal 2. To approve, in a non-binding vote, the appointment of Deloitte & Touche LLP to serve as the Company’s independent auditors for the fiscal year ending September 30, 2016, and to authorize, in a binding vote, the Audit Committee to set the auditors’ remuneration:

 

For:		Against:		Abstain:		Broker Non-Votes:
95,982,469		614,780		94,773		0

Proposal 3. To approve, in a non-binding advisory vote, the compensation of the Company’s named executive officers described in the proxy statement:

 

For:		Against:		Abstain:		Broker Non-Votes:
84,501,018		1,792,271		87,528		10,311,205

Proposal 4. To approve the Mallinckrodt Pharmaceuticals 2016 Employee Stock Purchase Plan:

 

For:		Against:		Abstain:		Broker Non-Votes:
85,804,525		519,027		57,265		10,311,205

Proposal 5. To authorize the Company and/or any subsidiary of the Company to make market purchases or overseas market purchases of Company shares:

 

For:		Against:		Abstain:		Broker Non-Votes:
96,121,569		167,793		402,660		0

Proposal 6. To authorize, via special resolution, the price range at which the Company can re-allot shares that it holds as treasury shares:

 

For:		Against:		Abstain:		Broker Non-Votes:
95,779,029		459,460		453,533		0

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.		Description
10.1		Mallinckrodt Pharmaceuticals 2016 Employee Stock Purchase Plan (incorporated by reference to Appendix A to the Company’s Proxy Statement filed on January 22, 2016).

 

3

---

SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 22, 2016

 

 

4

---

EXHIBIT INDEX

 

Exhibit No.		Description
10.1		Mallinckrodt Pharmaceuticals 2016 Employee Stock Purchase Plan (incorporated by reference to Appendix A to the Company’s Proxy Statement filed on January 22, 2016).

 

5